BiomX to Present at Upcoming November Investor Conferences

Download as PDF

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences.

Event: H.C. Wainwright 6th Annual Israel Conference (Virtual)
Date: Thursday, Nov. 12, 2020
Time: 9:30 a.m. EST
Webcast link: BiomX HCW Israel Conference Live Link and Playback

Event: Jefferies 2020 Virtual London Healthcare Conference
Date: Thursday, Nov. 19, 2020
Time: 12:00 p.m. EST
Webcast link: BiomX Jefferies London HC Conference Live Link and Playback.

Both live and archived webcasts will also be available in the Events section of the BiomX website at www.biomx.com.

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com.

Noel Kurdi, BiomX
VP Investor Relations and Strategy
(646) 241-4400
noelk@biomx.com

Media contact:
Rich Allan, Solebury Trout
(646) 378-2958
rallan@soleburytrout.com

Source: BiomX Inc.

Released November 10, 2020